1-15 of 15
Francesca Zammarchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted DNA Damage Boost with Loncastuximab Tesirine in Combination with PARP Inhibitors in Diffuse Large B-Cell Lymphoma

Stefania Fusani, Alessandra Rossi, Saveria Mazzara, Elena Baiardi, Stefania Orecchioni, Giovanna Talarico, Paolo Falvo, Francesca Zammarchi, Patrick Van Berkel, Stefano A. Pileri, Francesco Bertolini, Corrado Tarella, Enrico Derenzini
Journal: Blood
Blood (2023) 142 (Supplement 1): 5780.
https://doi.org/10.1182/blood-2023-188475
Published: 2023
Journal Articles

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni
Journal: Blood
Blood (2022) 140 (Supplement 1): 9548–9550.
https://doi.org/10.1182/blood-2022-159626
Published: 2022
Journal Articles

Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties

Jenny Yeung, Aiyin Liao, Matthew Shaw, Soraia Caetano-Silva, Winston Vetharoy, Ian Kirby, Francesca Zammarchi, Karin Havenith, Patrick H van Berkel, Claire Booth, H Bobby Gaspar, Adrian J. Thrasher, Kerry Chester, Persis J Amrolia
Journal: Blood
Blood (2022) 140 (Supplement 1): 10211–10212.
https://doi.org/10.1182/blood-2022-162390
Published: 2022
Journal Articles

CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors

Stefania Fusani, Alessandra Rossi, Saveria Mazzara, Elena Baiardi, Francesca Zammarchi, Patrick H van Berkel, Stefano A Pileri, Corrado Tarella, Enrico Derenzini
Journal: Blood
Blood (2021) 138 (Supplement 1): 1342.
https://doi.org/10.1182/blood-2021-150464
Published: 2021
Journal Articles

Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma

Nikoleta Sachini, Asma Jabeen, Patrick H van Berkel, Francesca Zammarchi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2273.
https://doi.org/10.1182/blood-2021-146800
Published: 2021
Journal Articles

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Filippo Spriano, Gaetanina Golino, PhD, Lorenzo Scalise, Emanuele Zucca, MD, Anastasios Stathis, MD, Patrick H Van Berkel, PhD, Francesca Zammarchi, PhD, Francesco Bertoni, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-134664
Published: 2020
Journal Articles

Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models

Asma Jabeen, PhD, Shiran Huang, John A. Hartley, PhD, Patrick H Van Berkel, PhD, Francesca Zammarchi, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-137004
Published: 2020
Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Jaewoong Lee, PhD, Kohei Kume, PhD, Zhengshan Chen, MD PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Liting Chen, PhD, Lai N Chan, PhD, Lars Klemm, MS, Chun-Wei David Chen, PhD, Ning Ma, PhD, Wing C. Chan, MD, Stephen J Forman, MD, Francesca Zammarchi, PhD, Patrick Van Berkel, PhD, Ari Melnick, MD, Vu N Ngo, PhD, Huimin Geng, PhD, Selina M. Luger, MD FRCPC, Mark Litzow, MD, Michael T McManus, PhD, Nagarajan Vaidehi, PhD, Elisabeth M. Paietta, PhD, Eric Meffre, PhD, David M. Weinstock, MD, Markus Müschen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 393.
https://doi.org/10.1182/blood-2019-131270
Published: 2019
Journal Articles

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Jae-Woong Lee, PhD, Kohei Kume, PhD, Zhengshan Chen, MDPhD, Gang Xiao, PhD, Kadriye Nehir Cosgun, PhD, Lai N Chan, Chun-Wei Chen, PhD, Raju Pillai, MD, Wing C Chan, MD, Stephen J Forman, Larry W Kwak, MD PhD, Francesca Zammarchi, PhD, Patrick Van Berkel, PhD, David M Weinstock, MD, Ari M Melnick, MD, Vu N Ngo, PhD, Huimin Geng, PhD, Selina Luger, MD, Mark R. Litzow, MD, Alexandre Belot, MDPhD, Gulbu Uzel, MD, Michael T McManus, PhD, Elisabeth M. Paietta, PhD, Eric Meffre, PhD, Markus Muschen, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 776.
https://doi.org/10.1182/blood-2018-99-117553
Published: 2018
Journal Articles

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter C. Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E. G. Havenith, Simon Chivers, Francois D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
Journal: Blood
Blood (2018) 131 (10): 1094–1105.
https://doi.org/10.1182/blood-2017-10-813493
Published: 2018
Includes: Supplemental data
Journal Articles

CD25 Enables Oncogenic BCR-Signaling and Represents a Therapeutic Target in B Cell Malignancies

Jaewoong Lee, PhD, Huimin Geng, PhD, Zhengshan Chen, MDPhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Francesca Zammarchi, PhD, Patrick Van Berkel, PhD, Ari Melnick, MD, Elisabeth Paietta, PhD, Markus Muschen, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3834.
https://doi.org/10.1182/blood.V130.Suppl_1.3834.3834
Published: 2017
Journal Articles

hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.

Francesca Zammarchi, PhD, Simon Corbett, Lauren Adams, Maria Mellinas-Gomez, PhD, Peter Tyrer, PhD, Sandamali Dissanayake, Simone Sims, Karin Havenith, PhD, Simon Chivers, PhD, David G Willimas, PhD, Philip W Howard, PhD, John A. Hartley, PhD, Patrick van Berkel, PhD
Journal: Blood
Blood (2016) 128 (22): 4176.
https://doi.org/10.1182/blood.V128.22.4176.4176
Published: 2016
Journal Articles

Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael J. Flynn, MD, Patrick H. van Berkel, PhD, Francesca Zammarchi, PhD, Peter C. Tyrer, PhD, Ayse U. Akarca, Narinder Janghra, Vishvesh Shende, PhD, Joseph Linares, Teresa Marafioti, MD, David G. Williams, PhD, Philip W. Howard, PhD, John A. Hartley, PhD
Journal: Blood
Blood (2015) 126 (23): 1559.
https://doi.org/10.1182/blood.V126.23.1559.1559
Published: 2015
Journal Articles

Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies

Francesca Zammarchi, PhD, David G. Williams, PhD, Lauren Adams, Karin Havenith, PhD, Simon Chivers, PhD, Francois D'Hooge, PhD, Philip W. Howard, PhD, John A. Hartley, PhD, Patrick H. van Berkel, PhD
Journal: Blood
Blood (2015) 126 (23): 1564.
https://doi.org/10.1182/blood.V126.23.1564.1564
Published: 2015
Journal Articles

Pre-Clinical Activity of Adct-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

Michael J Flynn, MBBCh, Patrick van Berkel, PhD, Francesca Zammarchi, PhD, Jean-Noel Levy, PhD, Arnaud Tiberghien, PhD, Luke A Masterson, PhD, François D'Hooge, PhD, Lauren Adams, David G Williams, PhD, Philip W Howard, PhD, John A Hartley, PhD
Journal: Blood
Blood (2014) 124 (21): 4491.
https://doi.org/10.1182/blood.V124.21.4491.4491
Published: 2014